Latigo 10-Q Reveals Material Weakness in Internal Controls Alongside Q2 Loss and IPO Details
LTGO sits 31% above its 52-week low of $17.22.
Summary
Latigo's first 10-Q discloses a material weakness in internal controls alongside its Q2 loss, reverse split details, and IPO economics.
Key Events · Earnings and Guidance · LTGO
-
Material Weakness in Internal Controls
Management concluded disclosure controls and procedures were not effective as of June 30, 2026 due to a material weakness: inadequate segregation of duties in the period-end financial reporting process, including the ability to create and post manual journal entries without independent review and to prepare and review account reconciliations.
-
Q2 Net Loss of $25.8M
Net loss was $25.8 million for Q2 2026, with R&D expenses of $21.2 million and G&A of $4.6 million. Six-month net loss was $48.8 million. Accumulated deficit reached $291.9 million.
-
Reverse Stock Split and IPO Details
A 1-for-6.42441 reverse stock split was effected July 28, 2026. The IPO sold 22,080,000 shares at $18.00 for $363.9 million net proceeds, including full exercise of the underwriters' 2,880,000-share option.
-
Convertible Notes and Derivative Liability
In June 2026, the company issued $35.0 million of convertible notes due June 2027 at 5.0% interest. A change-of-control repayment premium was bifurcated as a derivative liability initially valued at $5.1 million.
Analysis · LTGO · Life Sciences
Latigo's first 10-Q as a public company discloses a material weakness in internal control over financial reporting — inadequate segregation of duties in the period-end financial reporting process — which caused management to conclude disclosure controls were not effective as of June 30, 2026. This is a governance red flag that goes beyond the Q2 loss already reported in the concurrent 8-K. The filing also confirms the 1-for-6.42441 reverse stock split, the $35.0M convertible notes with a change-of-control derivative liability, and the full IPO economics: 22,080,000 shares at $18.00 for $363.9M net proceeds. Cash of $55.0M plus IPO proceeds funds operations into 2029, but the internal-control deficiency is the new material fact investors need to weigh.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1872 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LTGO was trading at $22.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $17.22 to $25.93. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.